

Dalbavancin

Restricted antimicrobial Please contact Microbiology/ID/Antimicrobial pharmacist for further information		
Form	500mg per vial dry powder for concentrate for solution for infusion.	
Reconstitution	 Slowly add 25 mL water for injection to each vial Do not shake. To avoid foaming, alternate between gentle swirling and inversion of vial until contents dissolved completely (approx. 5 minutes). Dilute further before administration 	
Compatibility & Stability	Glucose 5% ONLY	
Administration	Administer as an intravenous infusion of the second	ucose 5%
Monitoring	Rapid administration can cause reactions including flushing of the upper body, urticaria, pruritis and/or rash. Stopping or slowing the infusion may result in cessation of these reactions.	
Extravasation	Dalbavancin has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely using a recognised phlebitis scoring tool. Re-site cannula at first signs of inflammation.	
Additional Information	 If a common intravenous line is being used to administer other drugs in addition to dalbavancin, the line should be flushed before and after each dalbavancin administration with glucose 5% solution for infusion. Do not mix dalbavancin with any other medicinal products or intravenous solutions. 	

Information provided relates to Dalbavancin (Xydalba®) manufactured by AbbVie.